Skip to main content
Premium Trial:

Request an Annual Quote

NetGenics Licenses DiscoveryCenter to Avalon Pharmaceuticals

NEW YORK, Oct. 22 – NetGenics has licensed its DiscoveryCenter integration software product to Avalon Pharmaceuticals to help it integrate its genomic, cytogenetic, and chemistry data, Avalon said on Monday.

“We are building the next generation genomics drug discovery platform,'' Ken Carter PhD, Avalon's president and CEO, said in a statement. “DiscoveryCenter will play a key role in our success, as it provides us with the ability to integrate and analyze huge amounts of data, and NetGenics will provide a fundamental building block to our cutting edge bioinformatics platform.''

Financial terms of the agreement were not disclosed.

Last week, NetGenics, based in Cleveland, said it has completed the second phase of its DiscoveryCenter database build-out for Schering and its US subsidiary Berlex Laboratories. 

The three-part implementation, begun in June and scheduled to close around February 2002, provides a single point of access to curated and annotated gene-sequence and -expression data for Schering’s R&D scientists, according to NetGenics CEO Manual Glynias.

The Scan

Tens of Millions Saved

The Associated Press writes that vaccines against COVID-19 saved an estimated 20 million lives in their first year.

Supersized Bacterium

NPR reports that researchers have found and characterized a bacterium that is visible to the naked eye.

Also Subvariants

Moderna says its bivalent SARS-CoV-2 vaccine leads to a strong immune response against Omicron subvariants, the Wall Street Journal reports.

Science Papers Present Gene-Edited Mouse Models of Liver Cancer, Hürthle Cell Carcinoma Analysis

In Science this week: a collection of mouse models of primary liver cancer, and more.